Clinical and therapeutic experience in the remission of patients with acromegaly

Abstract

Objective: To analyze the clinical and therapeutic experience in the remission of patients with acromegaly at our center. Methods: The methodological design is based on an observational, descriptive, retrospective, and longitudinal study. Internal records were compiled through a review of medical records from the Endocrinology Department of the La Trinidad Teaching Medical Center from 2018 to 2025. A data collection instrument was designed to gather demographic and clinical data, including elevated GH and IGF-1 levels in patients with known acromegaly, imaging studies indicating PitNET findings, positive immunohistochemistry results for GH and GH-Prolactin without acromegalic syndrome, and patients who agreed to participate in the study. Results: Of the 12/16 patients with MacroPitNET (66.7%), 8 patients achieved remission versus 4 patients (33.3%) who did not. Furthermore, 2/16 patients (100%) with MicroPitNET achieved remission. Of these 10 patients, 50% achieved remission after surgery and radiotherapy, followed by 30% after surgery alone, and 20% after a combination of surgery and medication. Conclusion: In centers with extensive experience, acromegaly, a rare and complex disease, achieves better remission rates with transsphenoidal surgery combined with multimodal treatment in long-term follow-up. This study also demonstrated that surgical reintervention along with radiotherapy and medical therapy led to remission in almost 50% of patients with acromegaly.